Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1650 of 3499 entries
View as:

Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00075504 Org: User:
Start: 11/30/03 End: 01/31/09 Due: 01/31/10

506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00003545 Org: User:
Start: 08/31/98 End: - Due: -

Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Phase: N/A Priority: Normal
NCT ID: NCT00062244 Org: User:
Start: 05/31/03 End: - Due: -

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00059475 Org: User:
Start: 04/30/03 End: 05/31/10 Due: 05/31/11

CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor

Phase: N/A Priority: Normal
NCT ID: NCT00087074 Org: User:
Start: 06/30/04 End: - Due: -

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Phase: N/A Priority: Normal
NCT ID: NCT06865677 Org: User:
Start: 06/09/25 End: 12/30/27 Due: 12/30/28

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00077454 Org: User:
Start: 02/29/04 End: - Due: -

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00001337 Org: User:
Start: 05/08/93 End: 05/24/24 Due: 05/24/25

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04628767 Org: User:
Start: 11/12/21 End: 09/30/27 Due: 09/30/28

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

Phase: N/A Priority: Normal
NCT ID: NCT06982222 Org: User:
Start: 12/31/25 End: 02/12/27 Due: 02/12/28

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Phase: N/A Priority: Normal
NCT ID: NCT02682667 Org: User:
Start: 04/11/16 End: 12/01/27 Due: 12/01/28

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05904080 Org: User:
Start: 02/19/24 End: 06/16/28 Due: 06/16/29

Cell Lines From High-Risk Breast Tissue

Phase: N/A Priority: Normal
NCT ID: NCT00032201 Org: User:
Start: 03/06/02 End: 12/03/14 Due: 12/03/15

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02339571 Org: User:
Start: 11/23/15 End: 06/30/33 Due: 06/30/34

A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum

Phase: N/A Priority: Normal
NCT ID: NCT01134601 Org: User:
Start: 05/24/10 End: 10/22/12 Due: 10/22/13

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Phase: N/A Priority: Normal
NCT ID: NCT06661915 Org: User:
Start: 02/03/26 End: 12/31/27 Due: 12/31/28

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01915225 Org: User:
Start: 07/21/13 End: - Due: -

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06900595 Org: User:
Start: 07/31/25 End: 06/02/29 Due: 06/02/30

Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00275080 Org: User:
Start: 02/28/06 End: 08/31/14 Due: 08/31/15

Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer)

Phase: N/A Priority: Normal
NCT ID: NCT00019955 Org: User:
Start: 03/31/00 End: - Due: -

Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation

Phase: N/A Priority: Normal
NCT ID: NCT00342966 Org: User:
Start: 06/14/99 End: 07/23/10 Due: 07/23/11

Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China

Phase: N/A Priority: Normal
NCT ID: NCT00342472 Org: User:
Start: 02/12/98 End: 06/05/20 Due: 06/05/21

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00031915 Org: User:
Start: 06/30/02 End: 05/31/07 Due: 05/31/08

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03384316 Org: User:
Start: 01/31/18 End: 08/24/20 Due: 08/24/21

Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT02227901 Org: User:
Start: 09/30/02 End: 04/30/14 Due: 04/30/15